Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DMZ2YBE)
Drug Name | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
|
|||||||||||||||||||||||
Indication |
|
|||||||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||||||
Molecule(s) Related to This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
|
||||||||||||||||||||||||||
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
The Studied Disease | Nerve injury | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | ND56.4 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||
References